Abstract

BackgroundWe aimed to develop and validate a nomogram for predicting the disease-specific survival of Ewing sarcoma (ES) patients.MethodsThe Surveillance, Epidemiology, and End Results (SEER) program database was used to identify ES from 1990 to 2015, in which the data was extracted from 18 registries in the US. Multivariate analysis performed using Cox proportional hazards regression models was performed on the training set to identify independent prognostic factors and construct a nomogram for the prediction of the 3-, 5-, and 10-year survival rates of patients with ES. The predictive values were compared by using concordance indexes (C-indexes), calibration plots, integrated discrimination improvement (IDI), net reclassification improvement (NRI), and decision curve analysis (DCA).ResultsA total of 2,643 patients were identified. After multivariate Cox regression, a nomogram was established based on a new model containing the predictive variables of age, race, extent of disease, tumor size, and therapy of surgery. The new model provided better C-indexes (0.684 and 0.704 in the training and validation cohorts, respectively) than the model without therapy of surgery (0.661 and 0.668 in the training and validation cohorts, respectively). The good discrimination and calibration of the nomogram were demonstrated for both the training and validation cohorts. NRI and IDI were also improved. Finally, DCA demonstrated that the nomogram was clinically useful.ConclusionWe developed a reliable nomogram for determining the prognosis and treatment outcomes of patients with ES in the US. However, the proposed nomogram still requires external data verification in future applications, especially for regions outside the US.

Highlights

  • We aimed to develop and validate a nomogram for predicting the disease-specific survival of Ewing sarcoma (ES) patients

  • A composite socioeconomic status (SES) score corresponding to the percentage of persons in the country living below the national poverty threshold in the official 2000 census [6] was divided into three levels by using previously reported cutoff points [6, 7], namely, < 10%, 10–19.99%, and ≥ 20%

  • Demographic baseline characteristics The application of the inclusion and exclusion criteria listed in the Materials and Methods resulted in the identification of 2,643 patients with ES in the SEER program database

Read more

Summary

Introduction

We aimed to develop and validate a nomogram for predicting the disease-specific survival of Ewing sarcoma (ES) patients. Bone ES constitutes a family of malignant small round blue cell tumors with neuroectodermal origins, among which 85–90% have the classic t (11; 22) EWS/FLI1 translocation [1, 2]. The overall survival (OS) rate for ES has improved remarkably over the past two Nomograms are reliable and convenient tools for estimating tumor prognosis [4, 5]. The data of ES patients in the Surveillance, Epidemiology, and End Results (SEER) program database registries during 1990–2015 were screened and extracted. We analyzed the extracted data and subsequently created and validated a nomogram containing significant and reliable variables for quantifying the survival of ES patients

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call